LUPIN LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,610 INR | +1.62% |
|
-2.74% | +21.68% |
| May. 09 | Nomura Adjusts Lupin’s Price Target to INR1,952 From INR1,949, Keeps at Buy | MT |
| May. 09 | Lupin Limited Announces Board Appointments | CI |
Presentation Operator MessageOperator (Operator)Hello, everyone. Welcome to Quarter 3 FY '21 E...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Lupin Limited is a leading Indian pharmaceutical group. Its products are used to treat tuberculosis, diabetes, asthma, cardiovascular diseases, infections, etc. The group's activity is organized around 2 areas:
- design and production of generic and brand-name formulations;
- production of active pharmaceutical ingredients.
At the end of March 2022, the group had 15 production sites India (12), the United States, Mexico and Brazil.
Net sales break down geographically as follows: India (39.4%), the United States (34.1%) and other (26.5%).
Sector
Pharmaceuticals
Calendar
2024-08-06
- Q1 2025 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
HOLD
Number of Analysts
34
Last Close Price
1,610
INR
Average target price
1,547
INR
Spread / Average Target
-3.91%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +21.68% | 8.78B | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- LUPIN Stock
- News Lupin Limited
- Transcript : Lupin Limited, Q3 2021 Earnings Call, Jan 29, 2021